Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study
← catalyst calendarSponsored by Anteris Technologies Ltd. (industry) · AVR — their whole pipeline →.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Device feasibility
Enrollment
15actual
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-07 | actual | When the study began enrolling |
| Primary completion | 2023-12-29 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2033 | estimated | The whole study's end, after follow-up |
| First posted | 2023-02-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Aortic Stenosis
- Symptomatic Aortic Stenosis
- Severe Aortic Valve Stenosis
- Aortic Valve Calcification
Intervention
- Device: DurAVRTM THV System
Primary outcomes
what the primary-completion date above is the date OFAll-cause mortality or disabling stroke
measured 30days
Technical success
measured Immediate post procedure
Permalink · AVR's whole pipeline · Catalyst calendar · Every registered study · What changed